ARCHIVES

FDA advisors vote against recommending Johnson & Johnson’s Zarnestra for treatment of AML in the elderly.

This article is from The Cancer Letter archive.

Vol. 31 No. 18 | May 6, 2005

Download PDF Visit The Full Archive

Related Articles

Data Presented At Scientific Meetings Can Have Impact On Patient Treatment

March 31, 2006

DCE Advisors Approve New Epidemiology RFPs Table Proposed RFA

April 16, 1993

Studies Shed Light On Racial Disparities Between Blacks, Whites With Breast Cancer

July 31, 2009

In Brief: Cancer Research Institute to Support AIDS Grants, With Maximum $70,000 Each; Deadline Is Oct. 1

July 15, 1983

PDX Shows 27% Response In T-Cell Lymphoma In Study

December 26, 2008

Aromasin Approved By FDA For ER+ Early Breast Cancer

October 28, 2005